NEWS
Celleo Appoints Three Independent Non-Executive Directors
Celleo has appointed three experienced Non-Executive Directors to its Board. The appointments significantly boost the company’s governance depth and strategic growth focus.
The incoming Directors are Dr Alexander Gosling, Dr Colin White and Gordon Naylor. Together they add more than a century of experience at the forefront of global biopharmaceutical production, advanced automation and product manufacturing, and cutting-edge technology development across the life sciences.
“I’m delighted to welcome Dr Gosling, Dr White and Mr Naylor to Celleo’s Board,” announced David Kneen, CEO and co-founder. “The collective wisdom of such high-calibre individuals will be critical to effectively navigating Celleo along its continued growth trajectory, to the benefit of our customers, our investors, and ultimately patients in need.”
Dr Alexander Gosling has been elected as Chair. Hamish George, a Director at Bio101, has been appointed Company Secretary.
Dr Alexander Gosling AM
Dr Gosling is an industry veteran and Governance expert. He has a storied history as a Non-Executive Director at leading innovation and technology companies including Carina Biotech, TekCyte, Cyban, Micro-X and Australia’s Cell Therapy Manufacturing CRC. He was the founder and long-time Director of the life-science innovation hub Invetech.
“Immunotherapy has huge potential to deliver population-scale health impact, making the world a better place,” remarked Dr Gosling. “Effectively scaling cell therapy production will be transformative for the industry. That’s Celleo’s mission, and the key reason I joined the Board.”
Dr Colin White
Dr White brings deep experience in global life sciences system development, manufacturing, market engagement and supply. He is a Strategic Partner at global healthcare impact investment firm Archimed, and Non-Executive Director at Neo-Bionica and The Australian National Fabrication Facility. He was formerly a Senior Vice-President at Leica BioSystems.
“Medical innovation, particularly in therapeutics, typically comes in waves so transformational they define a new standard of care,” explained Dr White. “Celleo is accelerating the Cell Therapy wave by resolving one of its greatest challenges – scaling production at the economical cost of manufacture.”
Gordon Naylor
Mr Naylor has driven top-tier global biomanufacturing and blood plasma businesses, in both technical leadership and senior executive roles. He was formerly President, Chief Financial Officer and Executive Vice-President at CSL/Seqirus. He is a Non-Executive Director at Orica, and Non-Executive Director and Chair at Medical Developments International.
“Celleo is driving a rapid pace of technical development, and we plan to keep our first mover advantage,” commented Mr Naylor. “Collectively, the Board has experienced how to make that work. I think we are very well placed for success.”
Celleo continues to fortify its technical and commercial foundations through these appointments as the business establishes itself as a trusted supply partner to leading global biopharma. Celleo will commence delivery of GMP single-use sets and equipment to global charter customers in 2025.
NEWS
Celleo Appoints Three Independent Non-Executive Directors
Celleo has appointed three experienced Non-Executive Directors to its Board. The appointments significantly boost the company’s governance depth and strategic growth focus.
The incoming Directors are Dr Alexander Gosling, Dr Colin White and Gordon Naylor. Together they add more than a century of experience at the forefront of global biopharmaceutical production, advanced automation and product manufacturing, and cutting-edge technology development across the life sciences.
“I’m delighted to welcome Dr Gosling, Dr White and Mr Naylor to Celleo’s Board,” announced David Kneen, CEO and co-founder. “The collective wisdom of such high-calibre individuals will be critical to effectively navigating Celleo along its continued growth trajectory, to the benefit of our customers, our investors, and ultimately patients in need.”
Dr Alexander Gosling has been elected as Chair. Hamish George, a Director at Bio101, has been appointed Company Secretary.
Dr Alexander Gosling AM
Dr Gosling is an industry veteran and Governance expert. He has a storied history as a Non-Executive Director at leading innovation and technology companies including Carina Biotech, TekCyte, Cyban, Micro-X and Australia’s Cell Therapy Manufacturing CRC. He was the founder and long-time Director of the life-science innovation hub Invetech.
“Immunotherapy has huge potential to deliver population-scale health impact, making the world a better place,” remarked Dr Gosling. “Effectively scaling cell therapy production will be transformative for the industry. That’s Celleo’s mission, and the key reason I joined the Board.”
Dr Colin White
Dr White brings deep experience in global life sciences system development, manufacturing, market engagement and supply. He is a Strategic Partner at global healthcare impact investment firm Archimed, and Non-Executive Director at Neo-Bionica and The Australian National Fabrication Facility. He was formerly a Senior Vice-President at Leica BioSystems.
“Medical innovation, particularly in therapeutics, typically comes in waves so transformational they define a new standard of care,” explained Dr White. “Celleo is accelerating the Cell Therapy wave by resolving one of its greatest challenges – scaling production at the economical cost of manufacture.”
Gordon Naylor
Mr Naylor has driven top-tier global biomanufacturing and blood plasma businesses, in both technical leadership and senior executive roles. He was formerly President, Chief Financial Officer and Executive Vice-President at CSL/Seqirus. He is a Non-Executive Director at Orica, and Non-Executive Director and Chair at Medical Developments International.
“Celleo is driving a rapid pace of technical development, and we plan to keep our first mover advantage,” commented Mr Naylor. “Collectively, the Board has experienced how to make that work. I think we are very well placed for success.”
Celleo continues to fortify its technical and commercial foundations through these appointments as the business establishes itself as a trusted supply partner to leading global biopharma. Celleo will commence delivery of GMP single-use sets and equipment to global charter customers in 2025.
